As a result in the decline in COVID-19 cases nationwide, FDA announced that it would resume conducting domestic surveillance inspections on February 7—affecting all commodities. The agency will continue with mission-critical domestic and foreign inspections, and leverage remote assessments when necessary. FDA will also conduct previously planned foreign surveillance inspections that have received country clearance and fall within the CDC’s Level 1 or Level 2 COVID travel recommendation.
“Throughout all these activities, the agency remains committed to the health and safety of its investigators and will provide the protection needed to safely inspect facilities and conduct investigations at the ports and in agency laboratories.” – FDA
FDA’s plans to start foreign prioritized inspections in April.